PDS Biotechnology Corpora... (PDSB)
NASDAQ: PDSB
· Real-Time Price · USD
0.96
0.01 (1.34%)
At close: Oct 13, 2025, 3:59 PM
0.96
0.43%
Pre-market: Oct 14, 2025, 08:43 AM EDT
1.34% (1D)
| Bid | 0.67 |
| Market Cap | 44.6M |
| Revenue (ttm) | 59.07K |
| Net Income (ttm) | -36.6M |
| EPS (ttm) | -0.91 |
| PE Ratio (ttm) | -1.05 |
| Forward PE | -1.3 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 1.21 |
| Volume | 403,154 |
| Avg. Volume (20D) | 504,692 |
| Open | 0.95 |
| Previous Close | 0.95 |
| Day's Range | 0.93 - 0.98 |
| 52-Week Range | 0.85 - 3.48 |
| Beta | 1.10 |
| Ex-Dividend Date | n/a |
About PDSB
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol PDSB
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for PDSB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
+9.24%
PDS Biotechnology shares are trading higher after ...
Unlock content with
Pro Subscription
4 months ago
-0.63%
PDS Biotechnology shares are trading higher after the company announced phase 2 versamune HPV with pembrolizumab shows median overall survival of 39.3 months in CPS ≥20 patients with recurrent/metastatic HPV16-positive head and neck cancer.
